Novuson Surgical has developed a groundbreaking technology known as Direct Therapeutic Ultrasound (DTU), which represents a significant advancement in surgical energy technology, marking the first major innovation in over 25 years. This patented DTU technology is designed for precise targeting of vessel sealing, dividing, and hemostasis, effectively controlling bleeding in various surgical and trauma applications. Unlike traditional methods that rely on high-frequency electrical currents or mechanical friction, Novuson's DTU delivers energy in a controlled manner without passing electric current through the patient, thereby minimizing risks associated with electrical burns and improving overall safety during procedures.

In addition to the DTU technology, Novuson offers specialized devices such as the 3 mm Mini LS sealer/divider and the 10 mm UltraStat MAXX, which enhance surgical efficiency and patient outcomes. The Mini LS is the first of its kind, capable of sealing and dividing vessels up to 7 mm, making it ideal for minimally invasive surgeries where size and precision are critical. The UltraStat MAXX is designed for hemostasis in thicker tissues and organs, significantly reducing surgical and anesthesia time while minimizing the need for blood products. Together, these innovations not only improve surgical performance but also contribute to lower healthcare costs and better patient care.

United States

Novuson, a spinout from the University of Washington's highly regarded Applied Physics Laboratory's Center for Industrial and Medical Ultrasound, is developing its Direct Therapeutic Ultrasound (DTU) technology platform for coagulation and hemostatic control in surgical and trauma procedures.

Novuson Surgical

Company Details